Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial
Tóm tắt
Coupled plasma filtration adsorption (CPFA, Bellco, Italy), to remove inflammatory mediators from blood, has been proposed as a novel treatment for septic shock. This multicenter, randomised, non-blinded trial compared CPFA with standard care in the treatment of critically ill patients with septic shock.
Prospective, multicenter, randomised, open-label, two parallel group and superiority clinical trial.
18 Italian adult, general, intensive care units (ICUs).
Of the planned 330 adult patients with septic shock, 192 were randomised to either have CPFA added to the standard care, or not. The external monitoring committee excluded eight ineligible patients who were erroneously included.
CPFA was to be performed daily for 5 days, lasting at least 10 h/day.
The primary endpoint was mortality at discharge from the hospital at which the patient last stayed. Secondary endpoints were: 90-day mortality, new organ failures and ICU-free days within 30 days.
There was no statistical difference in hospital mortality (47.3% controls, 45.1% CPFA; p=0.76), nor in secondary endpoints, namely the occurrence of new organ failures (55.9% vs 56.0%; p=0.99) or free-ICU days during the first 30 days (6.8 vs 7.5; p=0.35). The study was terminated on the grounds of futility. Several patients randomised to CPFA were subsequently found to be undertreated. An a priori planned subgroup analysis showed those receiving a CPFA dose >0.18 L/kg/day had a lower mortality compared with controls (OR 0.36, 95% CI 0.13 to 0.99).
CPFA did not reduce mortality in patients with septic shock, nor did it positively affect other important clinical outcomes. A subgroup analysis suggested that CPFA could reduce mortality, when a high volume of plasma is treated. Owing to the inherent potential biases of such a subgroup analysis, this result can only be viewed as a hypothesis generator and should be confirmed in future studies.
NCT00332371;
Từ khóa
Tài liệu tham khảo
Tamayo, 2011, Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock, Eur Cytokine Netw, 22, 82, 10.1684/ecn.2011.0281
Human Medicines Evaluation Unit. Guidelines for good clinical practice. London: European Agency for the Evaluation of Medical Products, 1996:17–20.
Boffelli, 2006, Continuous quality improvement in intensive care medicine. The GiViTI Margherita Project—Report 2005, Minerva Anestesiol, 72, 419
Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–12.
Piantadosi S . Clinical trial. A methodological perspective. New York: Jonh Wiley & Sons, 1997.
Kleinbaum D Kupper L Morgenstern H . Epidemiologic research. New York, NY: Van Nostrand Reynhold, 1982.
Mariano, 2011, Citrate anticoagulation for continuous renal replacement therapy in critically Ill patients: success and limits, Int J Nephrol, 2011, 748320, 10.4061/2011/748320
Pozzato M Ferrari F Cecere P . Safety and efficacy of citrate anticoagulation in spetic shock patients treated with couplet plasma filtration adsorbtion (CPFA). J Am Soc Nephrol 2011;22—Congress Proceeding:605A.